Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 103

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 103
---
 | Patent Date    |     | Patent Number |     | Expiry Date       |
| Granted |     | US      |     | May 5, 2006      |     | 2006/0252717       |     | March 18, 2014 |     |     8,673,285 |     | February 18, 2027 |
| Granted |     | US      |     | February 2, 2006 |     | 2006/0171956       |     | March 5, 2011  |     |     7,906,122 |     | July 16, 2025     |

The new vaccine platform will utilize the
proprietary liposomal delivery system protected by the patents listed above, enabling targeted delivery and enhanced immunogenicity across
multiple infectious disease applications.

This proprietary liposomal delivery system
is designed to enhance antigen presentation and to elicit strong humoral and cellular immune responses. Preclinical studies in murine
models have demonstrated exceptionally high IgG titers, broad cross-variant neutralizing activity, and prolonged antigen retention at
the site of intradermal injection. Furthermore, the enzymatic removal of the purification tag has no adverse impact on immunogenicity,
confirming the clinical readiness of the tag-free formulation.

Beyond its application in COVID-19, where
it served as a proof-of-concept for the platform, the same liposomal protein-based vaccine technology is being extended to target West
Nile Virus (WNV). We believe that additional benefits may possibly include an improved safety profile, scalable production using non-mammalian
systems, and DIVA (Differentiating Infected from Vaccinated Individuals) compatibility.

The two U.S. patents referenced above relate
to the proprietary lipid-based delivery system developed in Prof. Chezy Barenholz’s laboratory at the Hebrew University of Jerusalem.
These patents, which expire in July 2025 and February 2027, respectively, protect the composition and method of use of a liposomal nanoparticle
platform incorporating ceramide carbamoyl spermine (CCS) for the delivery of recombinant protein antigens in vaccine formulations. They
include composition of matter claims and methods of use for prophylactic and therapeutic immunization.

This delivery system is designed to optimize
antigen presentation, enhance mucosal and systemic immunogenicity, and improve stability of co-encapsulated recombinant proteins, as
exemplified in preclinical studies involving S